Clinical analysis of leuprorelin combined with mifepristone tablets in the treatment of adenomyosis
亮丙瑞林联合米非司酮片治疗腺肌症的临床治疗效果分析

摘要

目的 分析对腺肌症患者施以亮丙瑞林、米非司酮片联合治疗的效果。方法 分析对象选择于2020.2~2021.2就诊于我院的腺肌症患者78例，随机数字法予以分组，施以亮丙瑞林、米非司酮片联合治疗的39例患者分入治疗组，施以亮丙瑞林单用治疗的39例患者分入对照组，对治疗效果（痛经情况、子宫体积、应激因子）进行对比和分析。结果 与对照组对比，治疗组患者各个时段（治疗后3个月、半年、1年）痛经评分均明显较低（P<0.05）；与对照组对比，治疗组治疗后子宫体积明显较小（P<0.05）；与对照组对比，治疗组患者治疗后应激因子（IL-6、IL-2、CRP）明显较好（P<0.05）。结论 对腺肌症患者施以亮丙瑞林、米非司酮片联合治疗效果突出，可改善患者痛经情况，减少子宫体积，减轻应激因子，建议推广。

Abstract

Objective To analyze the effect of leuproline and mifepristone tablets on patients with adenomyosis.
Methods 78 patients with adenomyosis treated in our hospital from February 2020 to February 2021 were randomly divided into two groups. 39 patients treated with leuprorelin and mifepristone tablets were divided into the treatment group and 39 patients treated with leuprorelin alone were divided into the control group. The treatment effects (dysmenorrhea, uterine volume and stress factors) were compared and analyzed.
Results compared with the control group, the dysmenorrhea scores of patients in the treatment group were significantly lower in each period (3 months, 6 months and 1 year after treatment) (P < 0.05); Compared with the control group, the volume of uterus in the treatment group was significantly smaller after treatment (P < 0.05); Compared with the control group, the stress factors (IL-6, IL-2, CRP) in the treatment group were significantly better (P < 0.05).
Conclusion   the combined treatment of leuproline and mifepristone tablets in patients with adenomyosis has outstanding effect, which can improve the dysmenorrhea, reduce the uterine volume and reduce stress factors. It is recommended to popularize it.